(Total Views: 138)
Posted On: 04/10/2024 5:18:21 PM
Post# of 94
NetworkNewsBreaks – InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Chief Science Officer to Present at This Month’s Europe Dermatology Drug Development Summit
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on the development of inflammation and immunology (“I&I”) biological products and on providing contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservices business unit, will be featured at this month’s annual Dermatology Drug Development Summit Europe. During the three-day gathering, SCNI chief science officer Dr. Tamar Ben-Yedidia will discuss the company’s NanoAbs as a local treatment for plaque psoriasis; Ben-Yedidia will be joined by Professor Michael Schön, director of the University Medical Center Göttingen’s Department of Dermatology, Venereology & Allergology. The summit is scheduled for April 16–18, 2024, in Berlin; SCNI’s presentation is slated to begin at 11 a.m. CET on April 17. In addition, Scinai CEO Amir Reichman will participate in a panel discussion titled “Route of Administration & Formulations: How Can We Improve?” That panel is also scheduled for April 17, and will begin at 2:45 p.m. CET. In their presentation, Ben-Yedidia and Schön will discuss the unmet need in the mild-to-moderate plaque psoriasis space as well as the clinical potential of a local therapy based on anti-IL-17A/F NanoAbs; the presentation will also provide results from ex-vivo 3D biologic human skin models suggesting the therapeutic potential of Scinai’s anti-IL-17A/F NanoAb and will include the use of a human xenograft model to evaluate anti-IL-17 NanoAbs as a local treatment for plaque psoriasis. The Dermatology Drug Development summit is designed to gather key opinion leaders and innovators in the dermatology field for a “pivotal platform aligning with rapid advancements and emerging needs across inflammatory skin disease treatments.”
NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on the development of inflammation and immunology (“I&I”) biological products and on providing contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservices business unit, will be featured at this month’s annual Dermatology Drug Development Summit Europe. During the three-day gathering, SCNI chief science officer Dr. Tamar Ben-Yedidia will discuss the company’s NanoAbs as a local treatment for plaque psoriasis; Ben-Yedidia will be joined by Professor Michael Schön, director of the University Medical Center Göttingen’s Department of Dermatology, Venereology & Allergology. The summit is scheduled for April 16–18, 2024, in Berlin; SCNI’s presentation is slated to begin at 11 a.m. CET on April 17. In addition, Scinai CEO Amir Reichman will participate in a panel discussion titled “Route of Administration & Formulations: How Can We Improve?” That panel is also scheduled for April 17, and will begin at 2:45 p.m. CET. In their presentation, Ben-Yedidia and Schön will discuss the unmet need in the mild-to-moderate plaque psoriasis space as well as the clinical potential of a local therapy based on anti-IL-17A/F NanoAbs; the presentation will also provide results from ex-vivo 3D biologic human skin models suggesting the therapeutic potential of Scinai’s anti-IL-17A/F NanoAb and will include the use of a human xenograft model to evaluate anti-IL-17 NanoAbs as a local treatment for plaque psoriasis. The Dermatology Drug Development summit is designed to gather key opinion leaders and innovators in the dermatology field for a “pivotal platform aligning with rapid advancements and emerging needs across inflammatory skin disease treatments.”
NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)
